vinorelbine tartrate

To model acquired resistance, PC-9 cells were exposed to vinorelbine or paclitaxel for 18 weeks-approximating the clinical duration of four adjuvant chemotherapy cycles-and subsequent drug sensitivity and signaling pathway alterations were assessed using cell viability assays, RNA sequencing, and immunoblotting. These findings suggest that CaMKII plays a critical role in EGFR-TKI resistance. This study underscores the importance of optimizing the timing of EGFR-TKI administration in the therapeutic sequence for EGFR-mutated NSCLC.

Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options.

Treatment included vinorelbine-based chemotherapy and cytokine-based immunotherapy using interleukin (IL)-15, IL-12, IL-23, and selenium...The dog survived for 241 days, including 143 days after stage IV diagnosis, exceeding previously reported outcomes. Although NK cell function was not directly evaluated, these findings raise the possibility that cytokine-based NK cell immunotherapy, when combined with chemotherapy, could have contributed to disease control and prolonged survival in advanced canine pulmonary adenocarcinoma.

P2, N=12, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=28 --> 12

Molecular events included the emergence of a BRAF V600E mutation responsive to dabrafenib plus trametinib and the acquisition of an EGFR exon 19 deletion responsive to Osimertinib. EVA/PCD identified activity for targeted agents and revealed synergy for vinorelbine plus Osimertinib not predicted by genomic profiling, which provided additional response. This case highlights clonal evolution in NSCLC and illustrates how serial tissue analyses correlating phenotypic and genomic events can offer therapeutic interventions to provide long-term survival. The integration of functional and genomic profiling may improve personalized treatment in NSCLC by interrogating tumor heterogeneity and clonal evolution to inform rational therapeutic selection.

P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 --> Jun 2028 | Trial primary completion date: Oct 2028 --> Jun 2028

P3, N=133, Recruiting, Intergroupe Francophone de Cancerologie Thoracique | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Nov 2025

P3, N=418, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting

P3, N=325, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026

No severe TAAEs were observed during the investigation. The triple regimen of inetetamab plus pyrotinib and vinorelbine exhibited promising therapeutic effects and was tolerable for participants with HER2-positive ABC.

P=N/A, N=29, Recruiting, University of Illinois at Chicago | Not yet recruiting --> Recruiting

P4, N=131, Not yet recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital